Serhat BOR, Murat GÜLŞEN, İlker TURAN, Müge TUNÇYÜREK, Tahsin TEKELİ, Abdurrahman KADAYIFÇI

Barrett özofagusunda yüksek dereceli displazi tedavisinde argon plazma koagulasyon: Vaka sunumu

Barrett özofagusu alt özofagus mukozasındaki normal skuamöz mukozanı n intestinal metaplazi bulunan metaplastik kolumnar epitelle yer değiştirmesidir. Non-displastik metaplazi düşük dereceli displazi, yüksek dereceli displazi ve sonuçta invaziv kansere ilerleyebilir. Özofajektomi ve anti-reflü tedavi ile beraber yakın endoskopik takibin yanında, endoskopik ablasyon tedavileri yüksek dereceli displazi içeren Barrett özofagusunun tedavisinde yeni bir tedavi modalitesidir. Burada, argon plazma koagulasyon ile başarılı şekilde tedavi edilen yüksek dereceli displazili Barrett özofaguslu bir olgu sunulmuştur.

Anahtar Kelimeler:

Barrret özofagus, displazi, argon plazma koagulasyon

Argon plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus: A case report

Barrett's esophagus is a metaplastic columnar replacement of the normal squamous lower esophageal mucosa to intestinal metaplasia. Non-dysplastic metaplasia can progress to low-grade dysplasia, high-grade dysplasia, and finally to invasive cancer. Besides esophajectomy and antireflux therapy with intensive endoscopic surveillance, endoscopic ablation therapy is a new treatment modality for Barrett's esophagus with high-grade dysplasia. Herein, we report a case of Barrett's esophagus with high-grade dysplasia successfully treated with argon plasma coagulation.

Keywords:

Barrrett's esophagus, Dysplasia, Argon plasma coagulation,

PDF

___

Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 1995; 109: 1541–6.
Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in reporting cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333–8.
Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett’s esophagus: results from a multi-center consortium. Dig Dis Sci 2003; 48: 1537–41.
Yilmaz N, Tuncer K, Tuncyurek M, et al. The prevalence of Barrett's esophagus and erosive esophagitis in a tertiary referral center in Turkey. Turk J Gastroenterol 2006; 17: 79-83.
Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for eradication of Barrett’s esophagus. Am J Gastroenterol 2000; 95: 1661-8.
Madisch A, Miehlke S, Bayerdörffer E, et al. Long-term follow-up after complete ablation of Barrett’s esophagus with argon plasma coagulation. World J Gastroenterol 2005; 11: 1182-6.
Mörk H, Al-Taie O, Berlin F, et al. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol 2007; 42: 23-7.
Basu KK, Pick B, Bale R, et al. Efficacy and one-year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut 2002; 51: 776-80.
Kadaleh M, van Laethem JL, Nagy N, et al. Long-term follow up and predictive of recurrence in Barrett’s esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002; 34: 1007-9.
Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607–19.
Attwood SE, Lewis CJ, Caplin S, et al. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol 2003; 1: 258-63.
Van Laethem JL, Jagodzinski R, Peny MO, et al. Argon plasma coagulation in the treatment of Barrett’s high grade dysplasia and in situ adenocarcinoma. Endoscopy 2001; 33: 257–61.
Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous reepithelialisation of Barrett’s oesophagus. Gut 2000; 46: 574-7.
Shand A, Dallal H, Palmer K, et al. Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut 2001; 48: 580-1.